SLCTR/2013/001已完成1 期
Evaluation of pharmacodynamic properties and the safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults
niversity of Colombo0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy human volunteers between 18 – 60 years of age
排除标准
- •1. Alcohol consumption >20 g/day
- •2. Diagnosed Alcoholic Liver Disease (ALD),
- •3. Cirrhosis
- •4. Abnormal baseline liver, renal function tests or other haematological parameters.
- •5. Any chronic illness.
- •6. Any long term medication including any nutritional supplements.
- •7. Lactation, pregnancy or unwillingness to use an effective form of birth control for women of child bearing years
研究者
相似试验
进行中（未招募）
1 期
Evaluation du raltégravir pendant le troisième trimestre de la grossesseHIV and pregnancyMedDRA version: 18.0Level: LLTClassification code 10073025Term: Prevention of mother to child transmission of HIV infectionSystem Organ Class: 100000004865EUCTR2013-004571-12-FRInserm-ANRS72
进行中（未招募）
不适用
Evaluation of pharmacokinetic and pharmacodynamic interactions between escitalopram and drugs used for the treatment of bipolar disorders. - NDbipolar disordersMedDRA version: 9.1Level: LLTClassification code 10057667Term: Bipolar disorderEUCTR2008-000370-20-ITAZIENDA OSPEDALIERA PISANA
已完成
1 期
A study to define the pharmacokinetic properties of lignocaine gel applied topically on a surgical fieldACTRN12611001201965Medortus Inc12
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200